GUFICBIO Gufic Biosciences Q4 FY26 results (Jan–Mar 2026) and concall
Gufic BioScience reported a strong Q4 FY26 with significant revenue and profit growth, driven by the Indore facility reaching breakeven and robust international business performance. Despite a slight decline in full-year PAT and EBITDA margin due to strategic investments and a working capital reset, management expressed confidence in future growth and margin expansion through new product launches, IP-led international expansion, and backward integration. The company is also preparing for US FDA inspection and launching new aesthetics products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 22.9%, net profit up 162.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 204 | 208 | 205 | 227 | 230 +13% | 231 +11% | 252 +23% |
| EBITDA | 39 | 34 | 27 | 32 | 36 −8% | 36 +6% | 46 +70% |
| Net profit | 22 | 19 | 8 | 12 | 15 −32% | 16 −16% | 21 +163% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
